Prakhar Vijayvargiya

Prakhar Vijayvargiya

Auto-generated profile, based on publicly available information

Prakhar Vijayvargiya

Division of Infectious Diseases, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
PVPrakhar Vijayvargiya
Prakhar Vijayvargiya
ZGZerelda Esquer Garrigos
Zerelda Esquer Garrigos
NANatalia E Castillo Almeida
Natalia E Castillo Almeida
PGPooja R. Gurram
Pooja R. Gurram
RSRyan W. Stevens
Ryan W. Stevens
RRRaymund R. Razonable
Raymund R. Razonable

10 October 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
AAAnna Apostolopoulou
Anna Apostolopoulou
ZGZerelda Esquer Garrigos
Zerelda Esquer Garrigos
PVPrakhar Vijayvargiya
Prakhar Vijayvargiya
RLRiver Lerner
River Lerner
DFDimitrios Farmakiotis
Dimitrios Farmakiotis
In this systematic review, we investigate the epidemiology, pathogenesis, risk factors, clinical manifestations, diagnosis and treatment of COVID-19-associated pulmonary aspergillosis (CAPA). We identified 85 cases from 22 studies. The frequency of CAPA is currently unknown but ranges between 30% in different case series; the possibility of colonization rather than invasive disease is the most important confounder. The vast majority of patients with CAPA did not have any of the classic host risk factors, such as immunosuppression from organ transplant or neutropenia, although a significant proportion (46%) had received corticosteroids. Age, pulmonary comorbidities and male sex were associated with higher mortality. Patients treated with voriconazole had numerically lower case-fatality rate. Clinical vigilance for CAPA is advisable in critically ill patients with COVID-19 who are not improving, even those who do not meet classic host criteria for invasive mycoses, especially if they are receiving corticosteroids. A thorough, multi-faceted diagnostic work-up and early initiation of a mold-active triazole may be lifesaving. Further research studies using standardized, uniform definitions of invasive disease and colonization are urgently needed.

1 February 2022 in Infectious Disease Clinics of North America
Verified
Journal Article
Closed access
RAR. Alfonso Hernandez Acosta
R. Alfonso Hernandez Acosta
ZGZerelda Esquer Garrigos
Zerelda Esquer Garrigos
JMJasmine R. Marcelin
Jasmine R. Marcelin
PVPrakhar Vijayvargiya
Prakhar Vijayvargiya

13 April 2023 in Pharmacy
Verified
Journal Article
Open access
PDF file
MVMary Kathryn Vance
Mary Kathryn Vance
DCDavid Arthur Cretella
David Arthur Cretella
LWLori M. Ward
Lori M. Ward
PVPrakhar Vijayvargiya
Prakhar Vijayvargiya
ZGZerelda Esquer Garrigos
Zerelda Esquer Garrigos
MWMary Joyce B. Wingler
Mary Joyce B. Wingler
(1) Background: Risk factors for extended-spectrum beta-lactamase (ESBL) infections could vary geographically. The purpose of this study was to identify local risk factors for ESBL production in patients with Gram-negative bacteremia. (2) Methods: This retrospective observational study included adult patients admitted from January 2019 to July 2021 and had positive blood cultures for E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis. Patients with ESBL infection were matched to a non-ESBL-producing infection with the same organism. (3) Results: A total of 150 patients were included: 50 in the ESBL group and 100 in the non-ESBL group. Patients in the ESBL group had a longer length of stay (11 vs. 7 days, p < 0.001), but not increased mortality (14% vs. 15%, p = 0.87) Multivariate analysis identified the receipt of >1 antibiotic in the last 90 days as a risk factor for ESBL infection (OR = 3.448, 95% CI = 1.494–7.957; p = 0.004); (4) Conclusions: Recent antimicrobial use was identified as an independent risk factors for ESBL-producing Enterobacterales infections. Knowledge of this risk may improve empirical therapy and reduce inappropriate use.

2 October 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PVPrakhar Vijayvargiya
Prakhar Vijayvargiya
PJPatricio R Jeraldo
Patricio R Jeraldo
MTMatthew J Thoendel
Matthew J Thoendel
KGKerryl E Greenwood-Quaintance
Kerryl E Greenwood-Quaintance
ZGZerelda Esquer Garrigos
Zerelda Esquer Garrigos
RPRobin Patel
Robin Patel
Vector-borne pathogens are a significant public health concern worldwide. Infections with these pathogens, some of which are emerging, are likely under-recognized due to the lack of widely-available laboratory tests. There is an urgent need for further advancement in diagnostic modalities to detect new and known vector-borne pathogens. We evaluated the utility of metagenomic shotgun sequencing (MGS) as a pathogen agnostic approach for detecting vector-borne pathogens from human blood samples. Residual whole blood samples from patients with known infection with Babesia microti, Borrelia hermsii, Plasmodium falciparum, Mansonella perstans, Anaplasma phagocytophilum or Ehrlichia chaffeensis were studied. Samples underwent DNA extraction, removal of human DNA, whole genome amplification, and paired-end library preparation, followed by sequencing on Illumina HiSeq 2500. Bioinformatic analysis was performed using the Livermore Metagenomics Analysis Toolkit (LMAT), Metagenomic Phylogenetic Analysis (MetaPhlAn2), Genomic Origin Through Taxonomic CHAllenge (GOTTCHA) and Kraken 2. Eight samples were included in the study (2 samples each for P. falciparum and A. phagocytophilum). An average of 27.5 million read pairs was generated per sample (range, 18.3–38.8 million) prior to removal of human reads. At least one of the analytic tools was able to detect four of six organisms at the genus level, and the organism present in five of eight specimens at the species level. Mansonella and Ehrlichia species were not detected by any of the tools; however, mitochondrial cytochrome c oxidase subunit I amino acid sequence analysis suggested the presence of M. perstans genetic material. MGS is a promising tool with the potential to evolve as a non-hypothesis driven diagnostic test to detect vector-borne pathogens, including protozoa and helminths.

1 April 2020 in Anaerobe
Verified
Journal Article
Closed access
PVPrakhar Vijayvargiya
Prakhar Vijayvargiya
ZGZerelda Esquer Garrigos
Zerelda Esquer Garrigos
KRKyle G. Rodino
Kyle G. Rodino
RRRaymund R. Razonable
Raymund R. Razonable
OSOmar M. Abu Saleh
Omar M. Abu Saleh